Combination therapy for resectable liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of treatments for people with liver cancer that can be surgically removed. The goal is to see if the combination helps shrink tumors and improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your liver cancer must be confirmed and at a stage where surgery is possible, but with some blood vessel involvement.
- You must not have had any prior treatment for your liver cancer, like chemotherapy, targeted therapy, or immunotherapy.
- Your liver function must be good (Child-Pugh class A), and you must be in generally good health (ECOG 0-1).
- You must not have certain other medical conditions, like active infections, severe heart disease, or a history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a combination of two drugs (bevacizumab and adebrelimab) plus a special procedure called TACE-HAIC to treat advanced liver cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective as a first-line treatment.
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) before surgery for liver cancer. The goal is to shrink tumors enough to make surgery possible or more effective.
This study tests a combination of three treatments (HAIC, lenvatinib, and cadonilimab) as a way to shrink liver tumors that cannot be removed with surgery. The goal is to make the tumors smaller so they might be removed later, and to see how safe and effective this combination is.
Hear when a new Liver Cancer (Primary and Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.